Document is current
Any future updates will be listed below
-
Authors
Fujimoto, Ayumi https://orcid.org/0000-0001-5406-9300
Miyazaki, Kana https://orcid.org/0000-0001-6547-3181
Yakushijin, Kimikazu https://orcid.org/0000-0003-2511-7857
Fujino, Takahiro https://orcid.org/0000-0001-7817-093X
Munakata, Wataru
Ejima, Yasuo
Maruyama, Dai
Kubota, Nobuko
Maeda, Takeshi
Takizawa, Jun
Hiramoto, Nobuhiro
Takeuchi, Masahiro
Sakai, Rika
Fukuhara, Noriko https://orcid.org/0000-0003-2682-2179
Taguchi, Senzo https://orcid.org/0000-0002-3932-8084
Asano, Naoko
Yamaguchi, Motoko
Suzuki, Ritsuro https://orcid.org/0000-0002-5974-7614
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (23K07833, 20K08731, 17K09924)
- License Information
-
More Information
Article History
Received: 4 October 2024
Revised: 13 December 2024
Accepted: 28 January 2025
First Online: 17 February 2025
Competing interests
: AF received honoraria from Chugai Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Sanofi K.K., and Meiji Seika Pharma Co., Ltd., outside of the submitted work. KM received research grants from Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, Sumitomo Pharma Co., Ltd., and Zenyaku Kogyo Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Limited, Janssen Pharmaceutical K.K., Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., AstraZeneca K.K., Bristol-Myers Squibb K.K., Meiji Seika Pharma Co., Ltd., Abbvie GK, Novartis Pharma K.K., Incyte Corporation, Asahi Kasei Pharma Corporation, Ono Pharmaceutical Co., Ltd., and Genmab A/S, outside of the submitted work. TF received honoraria from Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Nippon Shinyaku Co., Ltd., outside of the submitted work. WM received research grants from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Genmab A/S, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., and Nippon Shinyaku Co., Ltd., and received honoraria from Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Mundipharma K.K., Gilead Sciences Inc., MSD K.K., Amgen K.K., Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Novartis Pharma K.K., AstraZeneca K.K., Genmab A/S, Nippon Shinyaku Co., Ltd., and Abbvie GK, outside of the submitted work. DM received research funding from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Zenyaku Kogyo Co., Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Abbvie GK, AstraZeneca K.K., Bristol-Myers Squibb K.K., Genmab A/S, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Astellas Pharma Inc., and received honoraria from Ono Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Janssen Pharmaceutical K.K., Mundipharma K.K., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co. Ltd., MSD K.K., Zenyaku Kogyo Co., Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Abbvie GK, AstraZeneca K.K., Bristol-Myers Squibb K.K., Genmab A/S, and Novartis Pharma K.K., outside of the submitted work. TM received honoraria from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Novartis Pharma K.K., Sanofi K.K., Takeda Pharmaceutical Company Limited, Abbvie GK, Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and AstraZeneca K.K., outside of the submitted work. JT received scholarship from Kyowa Kirin Co., Ltd., Abbvie GK, and AstraZeneca K.K., received consulting fee from AstraZeneca K.K., Janssen Pharmaceutical K.K., and Abbvie GK, and received honoraria from AstraZeneca K.K., Janssen Pharmaceutical K.K., and Abbvie GK, outside of the submitted work. R Sakai received research grants from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd., and received honoraria from Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., SymBio Pharmaceuticals Limited, Janssen Pharmaceutical K.K., CSL Behring K.K., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Celgene Corporation, Bristol-Myers Squibb K.K., Mundipharma K.K., Meiji Seika Pharma Co., Ltd., and Towa Pharmaceutical Co., Ltd., outside of the submitted work. NF received research grants from Abbvie GK, Chugai Pharmaceutical Co., Ltd., Chordia therapeutics Inc., Genmab A/S, Incyte Corporation, Kyowa Kirin Co., Ltd., Loxo Oncology Inc., and Takeda Pharmaceutical Company Limited, and received honoraria from Abbvie GK, AstraZeneca K.K., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Eisai Co., Ltd., Eli Lilly and Company, Genmab A/S, Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Sanofi K.K., SymBio Pharmaceuticals Limited, and Takeda Pharmaceutical Company Limited, outside of the submitted work. NA has received honoraria from Takeda Pharmaceutical Company Limited, outside of the submitted work. MY received research funding from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Genmab A/S, Incyte Corporation and Abbvie GK, received consulting fees from Genmab A/S, BeiGene Ltd., and Nihon Servier Co. Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Abbvie GK, Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., MSD K.K., Nippon Shinyaku Co., Ltd., SymBio Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Eisai Co., Ltd., outside of the submitted work. R Suzuki received research grants from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Abbvie GK, Bristol-Myers Squibb K.K., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD K.K., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Limited, Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., and AstraZeneca K.K., outside of the submitted work. KY, YE, NK, NH, MT, and ST have no financial conflicts of interest to disclose.
